Iverson Genetics: Get Patients to INR Faster and Safer

If you have patients who take warfarin, you know that achieving a stable INR can be a challenge. Too little warfarin leaves patients at risk for thrombosis. Too much can promote adverse bleeding events. On average, 50% of major bleeding events associated with warfarin use occur in the first 90 days of treatment.

Achieving a stable INR often requires trial and error with frequent and costly testing. The elevated risk of bleeding complications occurring in patients with unstable INRs often sways many physicians from prescribing warfarin to patients who could greatly benefit from it. Today, with genetic testing, you have another tool to make warfarin dosing safer, less costly and more effective for your patients... To learn more, click here.